Clinical Trial

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma after progress of first-line standard therapy.
Trial Details
NCT Number NCT07621601
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Esophageal Squamous Cell Carcinoma (ESCC)
Enrollment 494 participants
Start Date 2026-07-31
Primary Completion 2030-12-31 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02